Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

NCT02451969 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1760

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

BIOLOGICAL: investigational 23-valent PPV
BIOLOGICAL: control 23-valent PPV

Sponsor

Sinovac Biotech Co., Ltd